excel: 25397
excel with dem: 20383
remove no baseline cre: 18319
remove missing esrd_kt!=0, eGFR_CRE_baseline <10 : 18157
remove missing last_cre_date< ICI_date:17937 (17752 with labs
after ici date)
remove 216 placebo :17721
remove 3 death_date < ici_date(RPDR error): 17718
all
| Characteristic |
N = 17,718 |
| age_ici |
66 (57, 74) |
| male |
|
| 0 |
8,303 (47%) |
| 1 |
9,415 (53%) |
| Race |
|
| Asian |
615 (3.5%) |
| Black |
545 (3.1%) |
| Other/Unknown |
817 (4.6%) |
| White |
15,741 (89%) |
| Ethnic_Group |
|
| Hispanic |
360 (2.0%) |
| Non_hispanic |
16,284 (92%) |
| Other |
1,074 (6.1%) |
| ckd_progression |
|
| 0 |
17,215 (99%) |
| 1 |
160 (0.9%) |
| Missing |
343 |
| ckd_incidence |
|
| 0 |
16,493 (95%) |
| 1 |
882 (5.1%) |
| Missing |
343 |
| eskd_composite |
|
| 0 |
17,614 (99%) |
| 1 |
104 (0.6%) |
| ckd_composite |
|
| 0 |
16,608 (94%) |
| 1 |
1,110 (6.3%) |
| ckd_stage_baseline |
|
| 1 |
8,474 (48%) |
| 2 |
6,676 (38%) |
| 3 |
2,378 (13%) |
| 4 |
179 (1.0%) |
| 5 |
11 (<0.1%) |
| aki |
|
| 0 |
12,618 (71%) |
| 1 |
5,100 (29%) |
| dm |
|
| 0 |
15,065 (85%) |
| 1 |
2,653 (15%) |
| htn |
|
| 0 |
7,012 (40%) |
| 1 |
10,706 (60%) |
| cad |
|
| 0 |
13,553 (76%) |
| 1 |
4,165 (24%) |
| cirrhosis |
|
| 0 |
17,284 (98%) |
| 1 |
434 (2.4%) |
| cancer_type |
|
| breast |
1,162 (6.6%) |
| cutaneous / melanoma |
2,775 (16%) |
| endocrine |
4 (<0.1%) |
| gi |
2,660 (15%) |
| gu |
2,104 (12%) |
| gyn |
938 (5.3%) |
| head and neck |
1,317 (7.4%) |
| heme |
846 (4.8%) |
| neuro |
814 (4.6%) |
| sarcoma |
214 (1.2%) |
| thoracic |
4,884 (28%) |
| cancer_group |
|
| cutaneous / melanoma |
2,775 (16%) |
| gi |
2,660 (15%) |
| gu |
2,104 (12%) |
| gyn |
938 (5.3%) |
| other |
4,357 (25%) |
| thoracic |
4,884 (28%) |
| ace_arb |
|
| 0 |
10,288 (58%) |
| 1 |
7,430 (42%) |
| diu |
|
| 0 |
8,343 (47%) |
| 1 |
9,375 (53%) |
| ppi |
|
| 0 |
5,080 (29%) |
| 1 |
12,638 (71%) |
| steroids |
|
| 0 |
4,561 (26%) |
| 1 |
13,157 (74%) |
| smoking |
|
| 0 |
8,835 (50%) |
| 1 |
8,883 (50%) |
| Bevacizumab |
|
| 0 |
16,445 (93%) |
| 1 |
1,273 (7.2%) |
| Cisplatin |
|
| 0 |
15,423 (87%) |
| 1 |
2,295 (13%) |
| Carboplatin |
|
| 0 |
12,237 (69%) |
| 1 |
5,481 (31%) |
| Pemetrexed |
|
| 0 |
15,391 (87%) |
| 1 |
2,327 (13%) |
| Gemcitabine |
|
| 0 |
15,674 (88%) |
| 1 |
2,044 (12%) |
| Cetuximab |
|
| 0 |
17,297 (98%) |
| 1 |
421 (2.4%) |
| Trastuzumab |
|
| 0 |
17,264 (97%) |
| 1 |
454 (2.6%) |
| VEGF_TKI |
|
| 0 |
16,472 (93%) |
| 1 |
1,246 (7.0%) |
| statins |
|
| 0 |
9,510 (54%) |
| 1 |
8,208 (46%) |
| ICI_Class |
|
| PD1 |
12,339 (70%) |
| Combination |
2,057 (12%) |
| CTLA4 |
758 (4.3%) |
| PDL1 |
2,564 (14%) |
| nephrotoxic_chemo |
|
| 0 |
9,138 (52%) |
| 1 |
8,580 (48%) |
| pre_CRE_180days |
0.85 (0.70, 1.04) |
| pre_HGB_180days |
12.20 (10.80, 13.50) |
| Missing |
12 |
| pre_ALB_180days |
4.00 (3.70, 4.30) |
| Missing |
45 |
| eGFR_CRE_baseline |
89 (71, 100) |
1year
| Characteristic |
N = 9,188 |
| age_ici |
66 (57, 73) |
| male |
|
| 0 |
4,387 (48%) |
| 1 |
4,801 (52%) |
| Race |
|
| Asian |
282 (3.1%) |
| Black |
264 (2.9%) |
| Other/Unknown |
388 (4.2%) |
| White |
8,254 (90%) |
| Ethnic_Group |
|
| Hispanic |
175 (1.9%) |
| Non_hispanic |
8,459 (92%) |
| Other |
554 (6.0%) |
| ckd_incidence_1year |
|
| 0 |
8,860 (96%) |
| 1 |
328 (3.6%) |
| ckd_progression_1year |
|
| 0 |
9,144 (100%) |
| 1 |
44 (0.5%) |
| eskd_composite_1year |
|
| 0 |
9,161 (100%) |
| 1 |
27 (0.3%) |
| ckd_composite_1year |
|
| 0 |
8,796 (96%) |
| 1 |
392 (4.3%) |
| ckd_stage_1year |
|
| 1 |
3,739 (41%) |
| 2 |
3,833 (42%) |
| 3 |
1,514 (16%) |
| 4 |
93 (1.0%) |
| 5 |
9 (<0.1%) |
| ckd_stage_baseline |
|
| 1 |
4,230 (46%) |
| 2 |
3,718 (40%) |
| 3 |
1,173 (13%) |
| 4 |
65 (0.7%) |
| 5 |
2 (<0.1%) |
| aki |
|
| 0 |
6,219 (68%) |
| 1 |
2,969 (32%) |
| dm |
|
| 0 |
7,927 (86%) |
| 1 |
1,261 (14%) |
| htn |
|
| 0 |
3,779 (41%) |
| 1 |
5,409 (59%) |
| cad |
|
| 0 |
7,270 (79%) |
| 1 |
1,918 (21%) |
| cirrhosis |
|
| 0 |
9,026 (98%) |
| 1 |
162 (1.8%) |
| ace_arb |
|
| 0 |
5,071 (55%) |
| 1 |
4,117 (45%) |
| diu |
|
| 0 |
4,339 (47%) |
| 1 |
4,849 (53%) |
| ppi |
|
| 0 |
2,545 (28%) |
| 1 |
6,643 (72%) |
| steroids |
|
| 0 |
2,454 (27%) |
| 1 |
6,734 (73%) |
| smoking |
|
| 0 |
4,487 (49%) |
| 1 |
4,701 (51%) |
| statins |
|
| 0 |
4,617 (50%) |
| 1 |
4,571 (50%) |
| ICI_Class |
|
| PD1 |
6,242 (68%) |
| Combination |
1,169 (13%) |
| CTLA4 |
421 (4.6%) |
| PDL1 |
1,356 (15%) |
| nephrotoxic_chemo |
|
| 0 |
4,784 (52%) |
| 1 |
4,404 (48%) |
| cancer_type |
|
| breast |
724 (7.9%) |
| cutaneous / melanoma |
1,899 (21%) |
| endocrine |
1 (<0.1%) |
| gi |
1,038 (11%) |
| gu |
1,246 (14%) |
| gyn |
493 (5.4%) |
| head and neck |
609 (6.6%) |
| heme |
493 (5.4%) |
| neuro |
293 (3.2%) |
| sarcoma |
104 (1.1%) |
| thoracic |
2,288 (25%) |
| cancer_group |
|
| cutaneous / melanoma |
1,899 (21%) |
| gi |
1,038 (11%) |
| gu |
1,246 (14%) |
| gyn |
493 (5.4%) |
| other |
2,224 (24%) |
| thoracic |
2,288 (25%) |
| pre_CRE_180days |
0.86 (0.72, 1.04) |
| pre_HGB_180days |
12.70 (11.40, 13.90) |
| Missing |
8 |
| pre_ALB_180days |
4.10 (3.90, 4.40) |
| Missing |
27 |
| eGFR_CRE_baseline |
88 (71, 99) |
2year
| Characteristic |
N = 5,856 |
| age_ici |
65 (56, 73) |
| male |
|
| 0 |
2,747 (47%) |
| 1 |
3,109 (53%) |
| Race |
|
| Asian |
159 (2.7%) |
| Black |
148 (2.5%) |
| Other/Unknown |
234 (4.0%) |
| White |
5,315 (91%) |
| Ethnic_Group |
|
| Hispanic |
95 (1.6%) |
| Non_hispanic |
5,392 (92%) |
| Other |
369 (6.3%) |
| ckd_incidence_2year |
|
| 0 |
5,436 (93%) |
| 1 |
420 (7.2%) |
| ckd_progression_2year |
|
| 0 |
5,798 (99%) |
| 1 |
58 (1.0%) |
| eskd_composite_2year |
|
| 0 |
5,831 (100%) |
| 1 |
25 (0.4%) |
| ckd_composite_2year |
|
| 0 |
5,364 (92%) |
| 1 |
492 (8.4%) |
| ckd_stage_1year |
|
| 1 |
2,268 (39%) |
| 2 |
2,573 (44%) |
| 3 |
962 (16%) |
| 4 |
50 (0.9%) |
| 5 |
3 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
2,168 (37%) |
| 2 |
2,616 (45%) |
| 3 |
1,005 (17%) |
| 4 |
61 (1.0%) |
| 5 |
6 (0.1%) |
| ckd_stage_baseline |
|
| 1 |
2,662 (45%) |
| 2 |
2,439 (42%) |
| 3 |
715 (12%) |
| 4 |
38 (0.6%) |
| 5 |
2 (<0.1%) |
| aki |
|
| 0 |
3,994 (68%) |
| 1 |
1,862 (32%) |
| dm |
|
| 0 |
5,093 (87%) |
| 1 |
763 (13%) |
| htn |
|
| 0 |
2,442 (42%) |
| 1 |
3,414 (58%) |
| cad |
|
| 0 |
4,677 (80%) |
| 1 |
1,179 (20%) |
| cirrhosis |
|
| 0 |
5,775 (99%) |
| 1 |
81 (1.4%) |
| ace_arb |
|
| 0 |
3,182 (54%) |
| 1 |
2,674 (46%) |
| diu |
|
| 0 |
2,824 (48%) |
| 1 |
3,032 (52%) |
| ppi |
|
| 0 |
1,616 (28%) |
| 1 |
4,240 (72%) |
| steroids |
|
| 0 |
1,598 (27%) |
| 1 |
4,258 (73%) |
| smoking |
|
| 0 |
2,868 (49%) |
| 1 |
2,988 (51%) |
| statins |
|
| 0 |
2,863 (49%) |
| 1 |
2,993 (51%) |
| ICI_Class |
|
| PD1 |
3,925 (67%) |
| Combination |
797 (14%) |
| CTLA4 |
319 (5.4%) |
| PDL1 |
815 (14%) |
| nephrotoxic_chemo |
|
| 0 |
3,328 (57%) |
| 1 |
2,528 (43%) |
| cancer_type |
|
| breast |
402 (6.9%) |
| cutaneous / melanoma |
1,436 (25%) |
| endocrine |
1 (<0.1%) |
| gi |
525 (9.0%) |
| gu |
836 (14%) |
| gyn |
303 (5.2%) |
| head and neck |
376 (6.4%) |
| heme |
355 (6.1%) |
| neuro |
150 (2.6%) |
| sarcoma |
64 (1.1%) |
| thoracic |
1,408 (24%) |
| cancer_group |
|
| cutaneous / melanoma |
1,436 (25%) |
| gi |
525 (9.0%) |
| gu |
836 (14%) |
| gyn |
303 (5.2%) |
| other |
1,348 (23%) |
| thoracic |
1,408 (24%) |
| pre_CRE_180days |
0.86 (0.72, 1.04) |
| pre_HGB_180days |
12.80 (11.50, 14.00) |
| Missing |
6 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
18 |
| eGFR_CRE_baseline |
88 (72, 99) |
3year
| Characteristic |
N = 3,655 |
| age_ici |
65 (56, 72) |
| male |
|
| 0 |
1,674 (46%) |
| 1 |
1,981 (54%) |
| Race |
|
| Asian |
83 (2.3%) |
| Black |
78 (2.1%) |
| Other/Unknown |
142 (3.9%) |
| White |
3,352 (92%) |
| Ethnic_Group |
|
| Hispanic |
55 (1.5%) |
| Non_hispanic |
3,374 (92%) |
| Other |
226 (6.2%) |
| ckd_incidence_3year |
|
| 0 |
3,305 (90%) |
| 1 |
350 (9.6%) |
| ckd_progression_3year |
|
| 0 |
3,599 (98%) |
| 1 |
56 (1.5%) |
| eskd_composite_3year |
|
| 0 |
3,638 (100%) |
| 1 |
17 (0.5%) |
| ckd_composite_3year |
|
| 0 |
3,240 (89%) |
| 1 |
415 (11%) |
| ckd_stage_1year |
|
| 1 |
1,423 (39%) |
| 2 |
1,625 (44%) |
| 3 |
577 (16%) |
| 4 |
28 (0.8%) |
| 5 |
2 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
1,341 (37%) |
| 2 |
1,686 (46%) |
| 3 |
600 (16%) |
| 4 |
27 (0.7%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
1,289 (35%) |
| 2 |
1,711 (47%) |
| 3 |
606 (17%) |
| 4 |
42 (1.1%) |
| 5 |
7 (0.2%) |
| ckd_stage_baseline |
|
| 1 |
1,678 (46%) |
| 2 |
1,525 (42%) |
| 3 |
435 (12%) |
| 4 |
16 (0.4%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
2,513 (69%) |
| 1 |
1,142 (31%) |
| dm |
|
| 0 |
3,209 (88%) |
| 1 |
446 (12%) |
| htn |
|
| 0 |
1,510 (41%) |
| 1 |
2,145 (59%) |
| cad |
|
| 0 |
2,947 (81%) |
| 1 |
708 (19%) |
| cirrhosis |
|
| 0 |
3,611 (99%) |
| 1 |
44 (1.2%) |
| ace_arb |
|
| 0 |
1,939 (53%) |
| 1 |
1,716 (47%) |
| diu |
|
| 0 |
1,735 (47%) |
| 1 |
1,920 (53%) |
| ppi |
|
| 0 |
983 (27%) |
| 1 |
2,672 (73%) |
| steroids |
|
| 0 |
998 (27%) |
| 1 |
2,657 (73%) |
| smoking |
|
| 0 |
1,757 (48%) |
| 1 |
1,898 (52%) |
| statins |
|
| 0 |
1,724 (47%) |
| 1 |
1,931 (53%) |
| ICI_Class |
|
| PD1 |
2,443 (67%) |
| Combination |
504 (14%) |
| CTLA4 |
221 (6.0%) |
| PDL1 |
487 (13%) |
| nephrotoxic_chemo |
|
| 0 |
2,232 (61%) |
| 1 |
1,423 (39%) |
| cancer_type |
|
| breast |
190 (5.2%) |
| cutaneous / melanoma |
1,047 (29%) |
| endocrine |
0 (0%) |
| gi |
258 (7.1%) |
| gu |
545 (15%) |
| gyn |
158 (4.3%) |
| head and neck |
244 (6.7%) |
| heme |
243 (6.6%) |
| neuro |
90 (2.5%) |
| sarcoma |
36 (1.0%) |
| thoracic |
844 (23%) |
| cancer_group |
|
| cutaneous / melanoma |
1,047 (29%) |
| gi |
258 (7.1%) |
| gu |
545 (15%) |
| gyn |
158 (4.3%) |
| other |
803 (22%) |
| thoracic |
844 (23%) |
| pre_CRE_180days |
0.87 (0.73, 1.04) |
| pre_HGB_180days |
13.00 (11.70, 14.10) |
| Missing |
5 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
13 |
| eGFR_CRE_baseline |
88 (72, 99) |
4year
| Characteristic |
N = 2,436 |
| age_ici |
64 (55, 71) |
| male |
|
| 0 |
1,112 (46%) |
| 1 |
1,324 (54%) |
| Race |
|
| Asian |
51 (2.1%) |
| Black |
43 (1.8%) |
| Other/Unknown |
90 (3.7%) |
| White |
2,252 (92%) |
| Ethnic_Group |
|
| Hispanic |
35 (1.4%) |
| Non_hispanic |
2,239 (92%) |
| Other |
162 (6.7%) |
| ckd_incidence_4year |
|
| 0 |
2,163 (89%) |
| 1 |
273 (11%) |
| ckd_progression_4year |
|
| 0 |
2,393 (98%) |
| 1 |
43 (1.8%) |
| eskd_composite_4year |
|
| 0 |
2,423 (99%) |
| 1 |
13 (0.5%) |
| ckd_composite_4year |
|
| 0 |
2,112 (87%) |
| 1 |
324 (13%) |
| ckd_stage_1year |
|
| 1 |
946 (39%) |
| 2 |
1,109 (46%) |
| 3 |
359 (15%) |
| 4 |
20 (0.8%) |
| 5 |
2 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
906 (37%) |
| 2 |
1,138 (47%) |
| 3 |
373 (15%) |
| 4 |
18 (0.7%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
846 (35%) |
| 2 |
1,181 (48%) |
| 3 |
387 (16%) |
| 4 |
19 (0.8%) |
| 5 |
3 (0.1%) |
| ckd_stage_4year |
|
| 1 |
878 (36%) |
| 2 |
1,112 (46%) |
| 3 |
420 (17%) |
| 4 |
24 (1.0%) |
| 5 |
2 (<0.1%) |
| ckd_stage_baseline |
|
| 1 |
1,144 (47%) |
| 2 |
1,005 (41%) |
| 3 |
278 (11%) |
| 4 |
8 (0.3%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
1,673 (69%) |
| 1 |
763 (31%) |
| dm |
|
| 0 |
2,155 (88%) |
| 1 |
281 (12%) |
| htn |
|
| 0 |
991 (41%) |
| 1 |
1,445 (59%) |
| cad |
|
| 0 |
1,962 (81%) |
| 1 |
474 (19%) |
| cirrhosis |
|
| 0 |
2,407 (99%) |
| 1 |
29 (1.2%) |
| ace_arb |
|
| 0 |
1,280 (53%) |
| 1 |
1,156 (47%) |
| diu |
|
| 0 |
1,163 (48%) |
| 1 |
1,273 (52%) |
| ppi |
|
| 0 |
608 (25%) |
| 1 |
1,828 (75%) |
| steroids |
|
| 0 |
687 (28%) |
| 1 |
1,749 (72%) |
| smoking |
|
| 0 |
1,172 (48%) |
| 1 |
1,264 (52%) |
| statins |
|
| 0 |
1,126 (46%) |
| 1 |
1,310 (54%) |
| ICI_Class |
|
| PD1 |
1,626 (67%) |
| Combination |
329 (14%) |
| CTLA4 |
158 (6.5%) |
| PDL1 |
323 (13%) |
| nephrotoxic_chemo |
|
| 0 |
1,572 (65%) |
| 1 |
864 (35%) |
| cancer_type |
|
| breast |
105 (4.3%) |
| cutaneous / melanoma |
803 (33%) |
| endocrine |
0 (0%) |
| gi |
144 (5.9%) |
| gu |
347 (14%) |
| gyn |
93 (3.8%) |
| head and neck |
163 (6.7%) |
| heme |
172 (7.1%) |
| neuro |
51 (2.1%) |
| sarcoma |
21 (0.9%) |
| thoracic |
537 (22%) |
| cancer_group |
|
| cutaneous / melanoma |
803 (33%) |
| gi |
144 (5.9%) |
| gu |
347 (14%) |
| gyn |
93 (3.8%) |
| other |
512 (21%) |
| thoracic |
537 (22%) |
| pre_CRE_180days |
0.87 (0.73, 1.04) |
| pre_HGB_180days |
13.10 (11.80, 14.20) |
| Missing |
1 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
7 |
| eGFR_CRE_baseline |
89 (73, 100) |
5year
| Characteristic |
N = 1,661 |
| age_ici |
63 (54, 70) |
| male |
|
| 0 |
757 (46%) |
| 1 |
904 (54%) |
| Race |
|
| Asian |
37 (2.2%) |
| Black |
25 (1.5%) |
| Other/Unknown |
58 (3.5%) |
| White |
1,541 (93%) |
| Ethnic_Group |
|
| Hispanic |
25 (1.5%) |
| Non_hispanic |
1,520 (92%) |
| Other |
116 (7.0%) |
| ckd_incidence_5year |
|
| 0 |
1,452 (87%) |
| 1 |
209 (13%) |
| ckd_progression_5year |
|
| 0 |
1,622 (98%) |
| 1 |
39 (2.3%) |
| eskd_composite_5year |
|
| 0 |
1,649 (99%) |
| 1 |
12 (0.7%) |
| ckd_composite_5year |
|
| 0 |
1,405 (85%) |
| 1 |
256 (15%) |
| ckd_stage_1year |
|
| 1 |
662 (40%) |
| 2 |
753 (45%) |
| 3 |
235 (14%) |
| 4 |
10 (0.6%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
620 (37%) |
| 2 |
793 (48%) |
| 3 |
238 (14%) |
| 4 |
9 (0.5%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
574 (35%) |
| 2 |
824 (50%) |
| 3 |
255 (15%) |
| 4 |
5 (0.3%) |
| 5 |
3 (0.2%) |
| ckd_stage_4year |
|
| 1 |
600 (36%) |
| 2 |
778 (47%) |
| 3 |
270 (16%) |
| 4 |
11 (0.7%) |
| 5 |
2 (0.1%) |
| ckd_stage_5year |
|
| 1 |
611 (37%) |
| 2 |
767 (46%) |
| 3 |
263 (16%) |
| 4 |
17 (1.0%) |
| 5 |
3 (0.2%) |
| ckd_stage_baseline |
|
| 1 |
801 (48%) |
| 2 |
680 (41%) |
| 3 |
174 (10%) |
| 4 |
6 (0.4%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
1,157 (70%) |
| 1 |
504 (30%) |
| dm |
|
| 0 |
1,484 (89%) |
| 1 |
177 (11%) |
| htn |
|
| 0 |
681 (41%) |
| 1 |
980 (59%) |
| cad |
|
| 0 |
1,356 (82%) |
| 1 |
305 (18%) |
| cirrhosis |
|
| 0 |
1,645 (99%) |
| 1 |
16 (1.0%) |
| ace_arb |
|
| 0 |
883 (53%) |
| 1 |
778 (47%) |
| diu |
|
| 0 |
787 (47%) |
| 1 |
874 (53%) |
| ppi |
|
| 0 |
402 (24%) |
| 1 |
1,259 (76%) |
| steroids |
|
| 0 |
477 (29%) |
| 1 |
1,184 (71%) |
| smoking |
|
| 0 |
809 (49%) |
| 1 |
852 (51%) |
| statins |
|
| 0 |
756 (46%) |
| 1 |
905 (54%) |
| ICI_Class |
|
| PD1 |
1,131 (68%) |
| Combination |
205 (12%) |
| CTLA4 |
119 (7.2%) |
| PDL1 |
206 (12%) |
| nephrotoxic_chemo |
|
| 0 |
1,105 (67%) |
| 1 |
556 (33%) |
| cancer_type |
|
| breast |
63 (3.8%) |
| cutaneous / melanoma |
629 (38%) |
| endocrine |
0 (0%) |
| gi |
75 (4.5%) |
| gu |
214 (13%) |
| gyn |
61 (3.7%) |
| head and neck |
113 (6.8%) |
| heme |
114 (6.9%) |
| neuro |
29 (1.7%) |
| sarcoma |
10 (0.6%) |
| thoracic |
353 (21%) |
| cancer_group |
|
| cutaneous / melanoma |
629 (38%) |
| gi |
75 (4.5%) |
| gu |
214 (13%) |
| gyn |
61 (3.7%) |
| other |
329 (20%) |
| thoracic |
353 (21%) |
| pre_CRE_180days |
0.87 (0.72, 1.03) |
| pre_HGB_180days |
13.20 (11.90, 14.20) |
| Missing |
1 |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
6 |
| eGFR_CRE_baseline |
89 (74, 100) |
6year
| Characteristic |
N = 1,079 |
| age_ici |
62 (53, 69) |
| male |
|
| 0 |
504 (47%) |
| 1 |
575 (53%) |
| Race |
|
| Asian |
18 (1.7%) |
| Black |
23 (2.1%) |
| Other/Unknown |
38 (3.5%) |
| White |
1,000 (93%) |
| Ethnic_Group |
|
| Hispanic |
14 (1.3%) |
| Non_hispanic |
982 (91%) |
| Other |
83 (7.7%) |
| ckd_incidence_6year |
|
| 0 |
932 (86%) |
| 1 |
147 (14%) |
| ckd_progression_6year |
|
| 0 |
1,050 (97%) |
| 1 |
29 (2.7%) |
| eskd_composite_6year |
|
| 0 |
1,070 (99%) |
| 1 |
9 (0.8%) |
| ckd_composite_6year |
181 (17%) |
| ckd_stage_1year |
|
| 1 |
459 (43%) |
| 2 |
481 (45%) |
| 3 |
134 (12%) |
| 4 |
4 (0.4%) |
| 5 |
1 (<0.1%) |
| ckd_stage_2year |
|
| 1 |
413 (38%) |
| 2 |
524 (49%) |
| 3 |
139 (13%) |
| 4 |
2 (0.2%) |
| 5 |
1 (<0.1%) |
| ckd_stage_3year |
|
| 1 |
378 (35%) |
| 2 |
543 (50%) |
| 3 |
154 (14%) |
| 4 |
3 (0.3%) |
| 5 |
1 (<0.1%) |
| ckd_stage_4year |
|
| 1 |
403 (37%) |
| 2 |
511 (47%) |
| 3 |
160 (15%) |
| 4 |
4 (0.4%) |
| 5 |
1 (<0.1%) |
| ckd_stage_5year |
|
| 1 |
416 (39%) |
| 2 |
500 (46%) |
| 3 |
152 (14%) |
| 4 |
9 (0.8%) |
| 5 |
2 (0.2%) |
| ckd_stage_6year |
|
| 1 |
402 (37%) |
| 2 |
503 (47%) |
| 3 |
159 (15%) |
| 4 |
12 (1.1%) |
| 5 |
3 (0.3%) |
| ckd_stage_baseline |
|
| 1 |
539 (50%) |
| 2 |
429 (40%) |
| 3 |
109 (10%) |
| 4 |
2 (0.2%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
768 (71%) |
| 1 |
311 (29%) |
| dm |
|
| 0 |
965 (89%) |
| 1 |
114 (11%) |
| htn |
|
| 0 |
436 (40%) |
| 1 |
643 (60%) |
| cad |
|
| 0 |
892 (83%) |
| 1 |
187 (17%) |
| cirrhosis |
|
| 0 |
1,069 (99%) |
| 1 |
10 (0.9%) |
| ace_arb |
|
| 0 |
581 (54%) |
| 1 |
498 (46%) |
| diu |
|
| 0 |
527 (49%) |
| 1 |
552 (51%) |
| ppi |
|
| 0 |
238 (22%) |
| 1 |
841 (78%) |
| steroids |
|
| 0 |
305 (28%) |
| 1 |
774 (72%) |
| smoking |
|
| 0 |
527 (49%) |
| 1 |
552 (51%) |
| statins |
|
| 0 |
488 (45%) |
| 1 |
591 (55%) |
| ICI_Class |
|
| PD1 |
721 (67%) |
| Combination |
120 (11%) |
| CTLA4 |
104 (9.6%) |
| PDL1 |
134 (12%) |
| nephrotoxic_chemo |
|
| 0 |
742 (69%) |
| 1 |
337 (31%) |
| cancer_type |
|
| breast |
41 (3.8%) |
| cutaneous / melanoma |
455 (42%) |
| endocrine |
0 (0%) |
| gi |
32 (3.0%) |
| gu |
124 (11%) |
| gyn |
38 (3.5%) |
| head and neck |
71 (6.6%) |
| heme |
83 (7.7%) |
| neuro |
13 (1.2%) |
| sarcoma |
3 (0.3%) |
| thoracic |
219 (20%) |
| cancer_group |
|
| cutaneous / melanoma |
455 (42%) |
| gi |
32 (3.0%) |
| gu |
124 (11%) |
| gyn |
38 (3.5%) |
| other |
211 (20%) |
| thoracic |
219 (20%) |
| pre_CRE_180days |
0.86 (0.72, 1.03) |
| pre_HGB_180days |
13.30 (12.10, 14.20) |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
3 |
| eGFR_CRE_baseline |
90 (75, 101) |
7year
| Characteristic |
N = 660 |
| age_ici |
61 (53, 69) |
| male |
|
| 0 |
299 (45%) |
| 1 |
361 (55%) |
| Race |
|
| Asian |
9 (1.4%) |
| Black |
15 (2.3%) |
| Other/Unknown |
24 (3.6%) |
| White |
612 (93%) |
| Ethnic_Group |
|
| Hispanic |
10 (1.5%) |
| Non_hispanic |
598 (91%) |
| Other |
52 (7.9%) |
| ckd_incidence_7year |
|
| 0 |
556 (84%) |
| 1 |
104 (16%) |
| ckd_progression_7year |
|
| 0 |
645 (98%) |
| 1 |
15 (2.3%) |
| eskd_composite_7year |
|
| 0 |
651 (99%) |
| 1 |
9 (1.4%) |
| ckd_composite_7year |
122 (18%) |
| ckd_stage_1year |
|
| 1 |
289 (44%) |
| 2 |
292 (44%) |
| 3 |
75 (11%) |
| 4 |
3 (0.5%) |
| 5 |
1 (0.2%) |
| ckd_stage_2year |
|
| 1 |
267 (40%) |
| 2 |
309 (47%) |
| 3 |
82 (12%) |
| 4 |
1 (0.2%) |
| 5 |
1 (0.2%) |
| ckd_stage_3year |
|
| 1 |
244 (37%) |
| 2 |
322 (49%) |
| 3 |
92 (14%) |
| 4 |
1 (0.2%) |
| 5 |
1 (0.2%) |
| ckd_stage_4year |
|
| 1 |
252 (38%) |
| 2 |
307 (47%) |
| 3 |
96 (15%) |
| 4 |
4 (0.6%) |
| 5 |
1 (0.2%) |
| ckd_stage_5year |
|
| 1 |
262 (40%) |
| 2 |
300 (45%) |
| 3 |
91 (14%) |
| 4 |
5 (0.8%) |
| 5 |
2 (0.3%) |
| ckd_stage_6year |
|
| 1 |
255 (39%) |
| 2 |
305 (46%) |
| 3 |
90 (14%) |
| 4 |
8 (1.2%) |
| 5 |
2 (0.3%) |
| ckd_stage_7year |
|
| 1 |
242 (37%) |
| 2 |
313 (47%) |
| 3 |
91 (14%) |
| 4 |
10 (1.5%) |
| 5 |
4 (0.6%) |
| ckd_stage_baseline |
|
| 1 |
340 (52%) |
| 2 |
255 (39%) |
| 3 |
63 (9.5%) |
| 4 |
2 (0.3%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
480 (73%) |
| 1 |
180 (27%) |
| dm |
|
| 0 |
584 (88%) |
| 1 |
76 (12%) |
| htn |
|
| 0 |
255 (39%) |
| 1 |
405 (61%) |
| cad |
|
| 0 |
557 (84%) |
| 1 |
103 (16%) |
| cirrhosis |
|
| 0 |
654 (99%) |
| 1 |
6 (0.9%) |
| ace_arb |
|
| 0 |
355 (54%) |
| 1 |
305 (46%) |
| diu |
|
| 0 |
317 (48%) |
| 1 |
343 (52%) |
| ppi |
|
| 0 |
133 (20%) |
| 1 |
527 (80%) |
| steroids |
|
| 0 |
194 (29%) |
| 1 |
466 (71%) |
| smoking |
|
| 0 |
324 (49%) |
| 1 |
336 (51%) |
| statins |
|
| 0 |
289 (44%) |
| 1 |
371 (56%) |
| ICI_Class |
|
| PD1 |
425 (64%) |
| Combination |
81 (12%) |
| CTLA4 |
84 (13%) |
| PDL1 |
70 (11%) |
| nephrotoxic_chemo |
|
| 0 |
490 (74%) |
| 1 |
170 (26%) |
| cancer_type |
|
| breast |
23 (3.5%) |
| cutaneous / melanoma |
325 (49%) |
| endocrine |
0 (0%) |
| gi |
14 (2.1%) |
| gu |
68 (10%) |
| gyn |
16 (2.4%) |
| head and neck |
31 (4.7%) |
| heme |
63 (9.5%) |
| neuro |
8 (1.2%) |
| sarcoma |
1 (0.2%) |
| thoracic |
111 (17%) |
| cancer_group |
|
| cutaneous / melanoma |
325 (49%) |
| gi |
14 (2.1%) |
| gu |
68 (10%) |
| gyn |
16 (2.4%) |
| other |
126 (19%) |
| thoracic |
111 (17%) |
| pre_CRE_180days |
0.86 (0.73, 1.04) |
| pre_HGB_180days |
13.20 (12.00, 14.15) |
| pre_ALB_180days |
4.20 (3.90, 4.40) |
| Missing |
3 |
| eGFR_CRE_baseline |
91 (74, 102) |
8year
| Characteristic |
N = 387 |
| age_ici |
62 (52, 69) |
| male |
|
| 0 |
160 (41%) |
| 1 |
227 (59%) |
| Race |
|
| Asian |
5 (1.3%) |
| Black |
7 (1.8%) |
| Other/Unknown |
8 (2.1%) |
| White |
367 (95%) |
| Ethnic_Group |
|
| Hispanic |
6 (1.6%) |
| Non_hispanic |
345 (89%) |
| Other |
36 (9.3%) |
| ckd_incidence_8year |
|
| 0 |
322 (83%) |
| 1 |
65 (17%) |
| ckd_progression_8year |
|
| 0 |
380 (98%) |
| 1 |
7 (1.8%) |
| eskd_composite_8year |
|
| 0 |
383 (99%) |
| 1 |
4 (1.0%) |
| ckd_composite_8year |
74 (19%) |
| ckd_stage_1year |
|
| 1 |
169 (44%) |
| 2 |
176 (45%) |
| 3 |
42 (11%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
156 (40%) |
| 2 |
184 (48%) |
| 3 |
47 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
145 (37%) |
| 2 |
192 (50%) |
| 3 |
50 (13%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
151 (39%) |
| 2 |
181 (47%) |
| 3 |
54 (14%) |
| 4 |
1 (0.3%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
153 (40%) |
| 2 |
176 (45%) |
| 3 |
56 (14%) |
| 4 |
2 (0.5%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
150 (39%) |
| 2 |
178 (46%) |
| 3 |
56 (14%) |
| 4 |
3 (0.8%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
149 (39%) |
| 2 |
180 (47%) |
| 3 |
53 (14%) |
| 4 |
5 (1.3%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
145 (37%) |
| 2 |
180 (47%) |
| 3 |
56 (14%) |
| 4 |
6 (1.6%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
201 (52%) |
| 2 |
149 (39%) |
| 3 |
37 (9.6%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
279 (72%) |
| 1 |
108 (28%) |
| dm |
|
| 0 |
347 (90%) |
| 1 |
40 (10%) |
| htn |
|
| 0 |
150 (39%) |
| 1 |
237 (61%) |
| cad |
|
| 0 |
329 (85%) |
| 1 |
58 (15%) |
| cirrhosis |
|
| 0 |
384 (99%) |
| 1 |
3 (0.8%) |
| ace_arb |
|
| 0 |
207 (53%) |
| 1 |
180 (47%) |
| diu |
|
| 0 |
189 (49%) |
| 1 |
198 (51%) |
| ppi |
|
| 0 |
81 (21%) |
| 1 |
306 (79%) |
| steroids |
|
| 0 |
136 (35%) |
| 1 |
251 (65%) |
| smoking |
|
| 0 |
203 (52%) |
| 1 |
184 (48%) |
| statins |
|
| 0 |
171 (44%) |
| 1 |
216 (56%) |
| ICI_Class |
|
| PD1 |
216 (56%) |
| Combination |
60 (16%) |
| CTLA4 |
70 (18%) |
| PDL1 |
41 (11%) |
| nephrotoxic_chemo |
|
| 0 |
307 (79%) |
| 1 |
80 (21%) |
| cancer_type |
|
| breast |
10 (2.6%) |
| cutaneous / melanoma |
226 (58%) |
| endocrine |
0 (0%) |
| gi |
5 (1.3%) |
| gu |
39 (10%) |
| gyn |
6 (1.6%) |
| head and neck |
9 (2.3%) |
| heme |
39 (10%) |
| neuro |
3 (0.8%) |
| sarcoma |
0 (0%) |
| thoracic |
50 (13%) |
| cancer_group |
|
| cutaneous / melanoma |
226 (58%) |
| gi |
5 (1.3%) |
| gu |
39 (10%) |
| gyn |
6 (1.6%) |
| other |
61 (16%) |
| thoracic |
50 (13%) |
| pre_CRE_180days |
0.87 (0.74, 1.03) |
| pre_HGB_180days |
13.20 (11.90, 14.20) |
| pre_ALB_180days |
4.20 (4.00, 4.40) |
| Missing |
2 |
| eGFR_CRE_baseline |
91 (75, 101) |
9year
| Characteristic |
N = 204 |
| age_ici |
60 (53, 68) |
| male |
|
| 0 |
90 (44%) |
| 1 |
114 (56%) |
| Race |
|
| Asian |
2 (1.0%) |
| Black |
2 (1.0%) |
| Other/Unknown |
3 (1.5%) |
| White |
197 (97%) |
| Ethnic_Group |
|
| Hispanic |
1 (0.5%) |
| Non_hispanic |
186 (91%) |
| Other |
17 (8.3%) |
| ckd_incidence_9year |
|
| 0 |
171 (84%) |
| 1 |
33 (16%) |
| ckd_progression_9year |
|
| 0 |
201 (99%) |
| 1 |
3 (1.5%) |
| eskd_composite_9year |
|
| 0 |
203 (100%) |
| 1 |
1 (0.5%) |
| ckd_composite_9year |
36 (18%) |
| ckd_stage_1year |
|
| 1 |
90 (44%) |
| 2 |
96 (47%) |
| 3 |
18 (8.8%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
85 (42%) |
| 2 |
100 (49%) |
| 3 |
19 (9.3%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
79 (39%) |
| 2 |
105 (51%) |
| 3 |
20 (9.8%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
88 (43%) |
| 2 |
92 (45%) |
| 3 |
24 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
87 (43%) |
| 2 |
89 (44%) |
| 3 |
28 (14%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
81 (40%) |
| 2 |
93 (46%) |
| 3 |
30 (15%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
88 (43%) |
| 2 |
87 (43%) |
| 3 |
29 (14%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
87 (43%) |
| 2 |
87 (43%) |
| 3 |
29 (14%) |
| 4 |
1 (0.5%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
89 (44%) |
| 2 |
81 (40%) |
| 3 |
34 (17%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
104 (51%) |
| 2 |
83 (41%) |
| 3 |
17 (8.3%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
150 (74%) |
| 1 |
54 (26%) |
| dm |
|
| 0 |
187 (92%) |
| 1 |
17 (8.3%) |
| htn |
|
| 0 |
72 (35%) |
| 1 |
132 (65%) |
| cad |
|
| 0 |
183 (90%) |
| 1 |
21 (10%) |
| cirrhosis |
|
| 0 |
203 (100%) |
| 1 |
1 (0.5%) |
| ace_arb |
|
| 0 |
116 (57%) |
| 1 |
88 (43%) |
| diu |
|
| 0 |
101 (50%) |
| 1 |
103 (50%) |
| ppi |
|
| 0 |
40 (20%) |
| 1 |
164 (80%) |
| steroids |
|
| 0 |
87 (43%) |
| 1 |
117 (57%) |
| smoking |
|
| 0 |
109 (53%) |
| 1 |
95 (47%) |
| statins |
|
| 0 |
89 (44%) |
| 1 |
115 (56%) |
| ICI_Class |
|
| PD1 |
95 (47%) |
| Combination |
36 (18%) |
| CTLA4 |
57 (28%) |
| PDL1 |
16 (7.8%) |
| nephrotoxic_chemo |
|
| 0 |
165 (81%) |
| 1 |
39 (19%) |
| cancer_type |
|
| breast |
5 (2.5%) |
| cutaneous / melanoma |
139 (68%) |
| endocrine |
0 (0%) |
| gi |
3 (1.5%) |
| gu |
14 (6.9%) |
| gyn |
1 (0.5%) |
| head and neck |
1 (0.5%) |
| heme |
22 (11%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
19 (9.3%) |
| cancer_group |
|
| cutaneous / melanoma |
139 (68%) |
| gi |
3 (1.5%) |
| gu |
14 (6.9%) |
| gyn |
1 (0.5%) |
| other |
28 (14%) |
| thoracic |
19 (9.3%) |
| pre_CRE_180days |
0.87 (0.76, 1.04) |
| pre_HGB_180days |
13.40 (11.95, 14.30) |
| pre_ALB_180days |
4.30 (4.10, 4.50) |
| eGFR_CRE_baseline |
91 (75, 102) |
10year
| Characteristic |
N = 73 |
| age_ici |
60 (51, 67) |
| male |
|
| 0 |
35 (48%) |
| 1 |
38 (52%) |
| Race |
|
| Asian |
0 (0%) |
| Black |
0 (0%) |
| Other/Unknown |
0 (0%) |
| White |
73 (100%) |
| Ethnic_Group |
|
| Hispanic |
0 (0%) |
| Non_hispanic |
69 (95%) |
| Other |
4 (5.5%) |
| ckd_incidence_10year |
|
| 0 |
61 (84%) |
| 1 |
12 (16%) |
| ckd_progression_10year |
|
| 0 |
71 (97%) |
| 1 |
2 (2.7%) |
| eskd_composite_10year |
|
| 0 |
72 (99%) |
| 1 |
1 (1.4%) |
| ckd_composite_10year |
14 (19%) |
| ckd_stage_1year |
|
| 1 |
33 (45%) |
| 2 |
30 (41%) |
| 3 |
10 (14%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_2year |
|
| 1 |
32 (44%) |
| 2 |
32 (44%) |
| 3 |
9 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_3year |
|
| 1 |
31 (42%) |
| 2 |
32 (44%) |
| 3 |
10 (14%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_4year |
|
| 1 |
31 (42%) |
| 2 |
30 (41%) |
| 3 |
12 (16%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_5year |
|
| 1 |
31 (42%) |
| 2 |
31 (42%) |
| 3 |
11 (15%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_6year |
|
| 1 |
28 (38%) |
| 2 |
34 (47%) |
| 3 |
11 (15%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_7year |
|
| 1 |
28 (38%) |
| 2 |
33 (45%) |
| 3 |
12 (16%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_8year |
|
| 1 |
27 (37%) |
| 2 |
33 (45%) |
| 3 |
12 (16%) |
| 4 |
1 (1.4%) |
| 5 |
0 (0%) |
| ckd_stage_9year |
|
| 1 |
30 (41%) |
| 2 |
30 (41%) |
| 3 |
13 (18%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| ckd_stage_10year |
|
| 1 |
28 (38%) |
| 2 |
33 (45%) |
| 3 |
9 (12%) |
| 4 |
3 (4.1%) |
| 5 |
0 (0%) |
| ckd_stage_baseline |
|
| 1 |
39 (53%) |
| 2 |
25 (34%) |
| 3 |
9 (12%) |
| 4 |
0 (0%) |
| 5 |
0 (0%) |
| aki |
|
| 0 |
53 (73%) |
| 1 |
20 (27%) |
| dm |
|
| 0 |
67 (92%) |
| 1 |
6 (8.2%) |
| htn |
|
| 0 |
26 (36%) |
| 1 |
47 (64%) |
| cad |
|
| 0 |
66 (90%) |
| 1 |
7 (9.6%) |
| cirrhosis |
|
| 0 |
73 (100%) |
| 1 |
0 (0%) |
| ace_arb |
|
| 0 |
38 (52%) |
| 1 |
35 (48%) |
| diu |
|
| 0 |
35 (48%) |
| 1 |
38 (52%) |
| ppi |
|
| 0 |
15 (21%) |
| 1 |
58 (79%) |
| steroids |
|
| 0 |
40 (55%) |
| 1 |
33 (45%) |
| smoking |
|
| 0 |
33 (45%) |
| 1 |
40 (55%) |
| statins |
|
| 0 |
27 (37%) |
| 1 |
46 (63%) |
| ICI_Class |
|
| PD1 |
25 (34%) |
| Combination |
6 (8.2%) |
| CTLA4 |
40 (55%) |
| PDL1 |
2 (2.7%) |
| nephrotoxic_chemo |
|
| 0 |
63 (86%) |
| 1 |
10 (14%) |
| cancer_type |
|
| breast |
2 (2.7%) |
| cutaneous / melanoma |
58 (79%) |
| endocrine |
0 (0%) |
| gi |
0 (0%) |
| gu |
3 (4.1%) |
| gyn |
0 (0%) |
| head and neck |
0 (0%) |
| heme |
5 (6.8%) |
| neuro |
0 (0%) |
| sarcoma |
0 (0%) |
| thoracic |
5 (6.8%) |
| cancer_group |
|
| cutaneous / melanoma |
58 (79%) |
| gi |
0 (0%) |
| gu |
3 (4.1%) |
| gyn |
0 (0%) |
| other |
7 (9.6%) |
| thoracic |
5 (6.8%) |
| pre_CRE_180days |
0.86 (0.78, 1.02) |
| pre_HGB_180days |
13.70 (12.60, 14.50) |
| pre_ALB_180days |
4.40 (4.20, 4.70) |
| eGFR_CRE_baseline |
91 (75, 101) |
CIF survival all Event number : death + ckd composite
ckd_stage vs ckd_composite_1year
|
0
(N=8796) |
1
(N=392) |
Overall
(N=9188) |
| ckd_stage_baseline |
|
|
|
| 1 |
4153 (47.2%) |
77 (19.6%) |
4230 (46.0%) |
| 2 |
3457 (39.3%) |
261 (66.6%) |
3718 (40.5%) |
| 3 |
1127 (12.8%) |
46 (11.7%) |
1173 (12.8%) |
| 4 |
58 (0.7%) |
7 (1.8%) |
65 (0.7%) |
| 5 |
1 (0.0%) |
1 (0.3%) |
2 (0.0%) |
| factor(ckd_stage_1year) |
|
|
|
| 1 |
3738 (42.5%) |
1 (0.3%) |
3739 (40.7%) |
| 2 |
3766 (42.8%) |
67 (17.1%) |
3833 (41.7%) |
| 3 |
1230 (14.0%) |
284 (72.4%) |
1514 (16.5%) |
| 4 |
59 (0.7%) |
34 (8.7%) |
93 (1.0%) |
| 5 |
3 (0.0%) |
6 (1.5%) |
9 (0.1%) |
ckd_stage vs ckd_composite_2year
|
0
(N=5364) |
1
(N=492) |
Overall
(N=5856) |
| ckd_stage_baseline |
|
|
|
| 1 |
2559 (47.7%) |
103 (20.9%) |
2662 (45.5%) |
| 2 |
2113 (39.4%) |
326 (66.3%) |
2439 (41.6%) |
| 3 |
659 (12.3%) |
56 (11.4%) |
715 (12.2%) |
| 4 |
32 (0.6%) |
6 (1.2%) |
38 (0.6%) |
| 5 |
1 (0.0%) |
1 (0.2%) |
2 (0.0%) |
| factor(ckd_stage_2year) |
|
|
|
| 1 |
2166 (40.4%) |
2 (0.4%) |
2168 (37.0%) |
| 2 |
2501 (46.6%) |
115 (23.4%) |
2616 (44.7%) |
| 3 |
660 (12.3%) |
345 (70.1%) |
1005 (17.2%) |
| 4 |
37 (0.7%) |
24 (4.9%) |
61 (1.0%) |
| 5 |
0 (0%) |
6 (1.2%) |
6 (0.1%) |
ckd_stage vs ckd_composite_3year
|
0
(N=3240) |
1
(N=415) |
Overall
(N=3655) |
| ckd_stage_baseline |
|
|
|
| 1 |
1585 (48.9%) |
93 (22.4%) |
1678 (45.9%) |
| 2 |
1262 (39.0%) |
263 (63.4%) |
1525 (41.7%) |
| 3 |
382 (11.8%) |
53 (12.8%) |
435 (11.9%) |
| 4 |
10 (0.3%) |
6 (1.4%) |
16 (0.4%) |
| 5 |
1 (0.0%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_3year) |
|
|
|
| 1 |
1279 (39.5%) |
10 (2.4%) |
1289 (35.3%) |
| 2 |
1576 (48.6%) |
135 (32.5%) |
1711 (46.8%) |
| 3 |
366 (11.3%) |
240 (57.8%) |
606 (16.6%) |
| 4 |
19 (0.6%) |
23 (5.5%) |
42 (1.1%) |
| 5 |
0 (0%) |
7 (1.7%) |
7 (0.2%) |
ckd_stage vs ckd_composite_4year
|
0
(N=2112) |
1
(N=324) |
Overall
(N=2436) |
| ckd_stage_baseline |
|
|
|
| 1 |
1070 (50.7%) |
74 (22.8%) |
1144 (47.0%) |
| 2 |
799 (37.8%) |
206 (63.6%) |
1005 (41.3%) |
| 3 |
236 (11.2%) |
42 (13.0%) |
278 (11.4%) |
| 4 |
6 (0.3%) |
2 (0.6%) |
8 (0.3%) |
| 5 |
1 (0.0%) |
0 (0%) |
1 (0.0%) |
| factor(ckd_stage_4year) |
|
|
|
| 1 |
865 (41.0%) |
13 (4.0%) |
878 (36.0%) |
| 2 |
1013 (48.0%) |
99 (30.6%) |
1112 (45.6%) |
| 3 |
225 (10.7%) |
195 (60.2%) |
420 (17.2%) |
| 4 |
9 (0.4%) |
15 (4.6%) |
24 (1.0%) |
| 5 |
0 (0%) |
2 (0.6%) |
2 (0.1%) |
ckd_stage vs ckd_composite_5year
|
0
(N=1405) |
1
(N=256) |
Overall
(N=1661) |
| ckd_stage_baseline |
|
|
|
| 1 |
742 (52.8%) |
59 (23.0%) |
801 (48.2%) |
| 2 |
524 (37.3%) |
156 (60.9%) |
680 (40.9%) |
| 3 |
135 (9.6%) |
39 (15.2%) |
174 (10.5%) |
| 4 |
4 (0.3%) |
2 (0.8%) |
6 (0.4%) |
| 5 |
0 (0%) |
0 (0%) |
0 (0%) |
| factor(ckd_stage_5year) |
|
|
|
| 1 |
599 (42.6%) |
12 (4.7%) |
611 (36.8%) |
| 2 |
669 (47.6%) |
98 (38.3%) |
767 (46.2%) |
| 3 |
132 (9.4%) |
131 (51.2%) |
263 (15.8%) |
| 4 |
5 (0.4%) |
12 (4.7%) |
17 (1.0%) |
| 5 |
0 (0%) |
3 (1.2%) |
3 (0.2%) |
Table 5 year aki
|
Overall
(N=256) |
| aki |
|
| 0 |
112 (43.8%) |
| 1 |
144 (56.3%) |
| as.factor(aki_before_ckd) |
|
| 0 |
47 (18.4%) |
| 1 |
97 (37.9%) |
| Missing |
112 (43.8%) |
|
Overall
(N=17718) |
| aki |
|
| 0 |
12618 (71.2%) |
| 1 |
5100 (28.8%) |
| as.factor(aki_before_ckd) |
|
| 0 |
210 (1.2%) |
| 1 |
450 (2.5%) |
| Missing |
17058 (96.3%) |
| ckd_composite |
|
| 0 |
16608 (93.7%) |
| 1 |
1110 (6.3%) |
Table ckd_composite==1 columns:aki_before_ckd
| Characteristic |
N = 1,032 |
| age_ici |
70 (63, 76) |
| male |
|
| 0 |
516 (50%) |
| 1 |
516 (50%) |
| Race |
|
| Asian |
22 (2.1%) |
| Black |
28 (2.7%) |
| Other/Unknown |
33 (3.2%) |
| White |
949 (92%) |
| Ethnic_Group |
|
| Hispanic |
20 (1.9%) |
| Non_hispanic |
952 (92%) |
| Other |
60 (5.8%) |
| ckd_incidence_1year |
|
| 0 |
704 (68%) |
| 1 |
328 (32%) |
| ckd_progression_1year |
|
| 0 |
988 (96%) |
| 1 |
44 (4.3%) |
| eskd_composite_1year |
|
| 0 |
1,005 (97%) |
| 1 |
27 (2.6%) |
| ckd_composite_1year |
|
| 0 |
640 (62%) |
| 1 |
392 (38%) |
| ckd_stage_1year |
|
| 1 |
76 (7.4%) |
| 2 |
434 (42%) |
| 3 |
472 (46%) |
| 4 |
44 (4.3%) |
| 5 |
6 (0.6%) |
| ckd_stage_baseline |
|
| 1 |
227 (22%) |
| 2 |
639 (62%) |
| 3 |
152 (15%) |
| 4 |
13 (1.3%) |
| 5 |
1 (<0.1%) |
| aki |
|
| 0 |
433 (42%) |
| 1 |
599 (58%) |
| dm |
|
| 0 |
825 (80%) |
| 1 |
207 (20%) |
| htn |
|
| 0 |
315 (31%) |
| 1 |
717 (69%) |
| cad |
|
| 0 |
757 (73%) |
| 1 |
275 (27%) |
| cirrhosis |
|
| 0 |
1,016 (98%) |
| 1 |
16 (1.6%) |
| ace_arb |
|
| 0 |
406 (39%) |
| 1 |
626 (61%) |
| diu |
|
| 0 |
328 (32%) |
| 1 |
704 (68%) |
| ppi |
|
| 0 |
219 (21%) |
| 1 |
813 (79%) |
| steroids |
|
| 0 |
292 (28%) |
| 1 |
740 (72%) |
| smoking |
|
| 0 |
422 (41%) |
| 1 |
610 (59%) |
| statins |
|
| 0 |
379 (37%) |
| 1 |
653 (63%) |
| ICI_Class |
|
| PD1 |
696 (67%) |
| Combination |
125 (12%) |
| CTLA4 |
55 (5.3%) |
| PDL1 |
156 (15%) |
| nephrotoxic_chemo |
|
| 0 |
548 (53%) |
| 1 |
484 (47%) |
| cancer_type |
|
| breast |
34 (3.3%) |
| cutaneous / melanoma |
188 (18%) |
| endocrine |
1 (<0.1%) |
| gi |
118 (11%) |
| gu |
199 (19%) |
| gyn |
47 (4.6%) |
| head and neck |
48 (4.7%) |
| heme |
41 (4.0%) |
| neuro |
12 (1.2%) |
| sarcoma |
7 (0.7%) |
| thoracic |
337 (33%) |
| cancer_group |
|
| cutaneous / melanoma |
188 (18%) |
| gi |
118 (11%) |
| gu |
199 (19%) |
| gyn |
47 (4.6%) |
| other |
143 (14%) |
| thoracic |
337 (33%) |
| pre_CRE_180days |
0.93 (0.79, 1.12) |
| pre_HGB_180days |
12.40 (11.10, 13.50) |
| Missing |
1 |
| pre_ALB_180days |
4.00 (3.80, 4.30) |
| Missing |
3 |
| eGFR_CRE_baseline |
78 (67, 88) |
| Characteristic |
0
N = 660 |
1
N = 450 |
| age_ici |
71 (64, 77) |
69 (62, 75) |
| male |
|
|
| 0 |
328 (50%) |
224 (50%) |
| 1 |
332 (50%) |
226 (50%) |
| Race |
|
|
| Asian |
18 (2.7%) |
8 (1.8%) |
| Black |
18 (2.7%) |
13 (2.9%) |
| Other/Unknown |
25 (3.8%) |
13 (2.9%) |
| White |
599 (91%) |
416 (92%) |
| Ethnic_Group |
|
|
| Hispanic |
12 (1.8%) |
11 (2.4%) |
| Non_hispanic |
609 (92%) |
415 (92%) |
| Other |
39 (5.9%) |
24 (5.3%) |
| ckd_composite |
|
|
| 0 |
0 (0%) |
0 (0%) |
| 1 |
660 (100%) |
450 (100%) |
| ckd_incidence |
|
|
| 0 |
108 (16%) |
120 (27%) |
| 1 |
552 (84%) |
330 (73%) |
| ckd_progression |
|
|
| 0 |
577 (87%) |
373 (83%) |
| 1 |
83 (13%) |
77 (17%) |
| ckd_stage_baseline |
|
|
| 1 |
123 (19%) |
115 (26%) |
| 2 |
441 (67%) |
240 (53%) |
| 3 |
85 (13%) |
84 (19%) |
| 4 |
9 (1.4%) |
10 (2.2%) |
| 5 |
2 (0.3%) |
1 (0.2%) |
| aki |
|
|
| 0 |
450 (68%) |
0 (0%) |
| 1 |
210 (32%) |
450 (100%) |
| dm |
|
|
| 0 |
531 (80%) |
346 (77%) |
| 1 |
129 (20%) |
104 (23%) |
| htn |
|
|
| 0 |
197 (30%) |
137 (30%) |
| 1 |
463 (70%) |
313 (70%) |
| cad |
|
|
| 0 |
487 (74%) |
323 (72%) |
| 1 |
173 (26%) |
127 (28%) |
| cirrhosis |
|
|
| 0 |
652 (99%) |
437 (97%) |
| 1 |
8 (1.2%) |
13 (2.9%) |
| cancer_type |
|
|
| breast |
17 (2.6%) |
21 (4.7%) |
| cutaneous / melanoma |
116 (18%) |
77 (17%) |
| endocrine |
0 (0%) |
1 (0.2%) |
| gi |
74 (11%) |
59 (13%) |
| gu |
124 (19%) |
94 (21%) |
| gyn |
32 (4.8%) |
17 (3.8%) |
| head and neck |
25 (3.8%) |
23 (5.1%) |
| heme |
23 (3.5%) |
25 (5.6%) |
| neuro |
6 (0.9%) |
6 (1.3%) |
| sarcoma |
3 (0.5%) |
5 (1.1%) |
| thoracic |
240 (36%) |
122 (27%) |
| cancer_group |
|
|
| cutaneous / melanoma |
116 (18%) |
77 (17%) |
| gi |
74 (11%) |
59 (13%) |
| gu |
124 (19%) |
94 (21%) |
| gyn |
32 (4.8%) |
17 (3.8%) |
| other |
74 (11%) |
81 (18%) |
| thoracic |
240 (36%) |
122 (27%) |
| ace_arb |
|
|
| 0 |
288 (44%) |
148 (33%) |
| 1 |
372 (56%) |
302 (67%) |
| diu |
|
|
| 0 |
240 (36%) |
108 (24%) |
| 1 |
420 (64%) |
342 (76%) |
| ppi |
|
|
| 0 |
172 (26%) |
69 (15%) |
| 1 |
488 (74%) |
381 (85%) |
| steroids |
|
|
| 0 |
183 (28%) |
128 (28%) |
| 1 |
477 (72%) |
322 (72%) |
| smoking |
|
|
| 0 |
282 (43%) |
172 (38%) |
| 1 |
378 (57%) |
278 (62%) |
| statins |
|
|
| 0 |
264 (40%) |
145 (32%) |
| 1 |
396 (60%) |
305 (68%) |
| ICI_Class |
|
|
| PD1 |
447 (68%) |
298 (66%) |
| Combination |
74 (11%) |
59 (13%) |
| CTLA4 |
32 (4.8%) |
27 (6.0%) |
| PDL1 |
107 (16%) |
66 (15%) |
| nephrotoxic_chemo |
|
|
| 0 |
343 (52%) |
243 (54%) |
| 1 |
317 (48%) |
207 (46%) |
| pre_CRE_180days |
0.94 (0.80, 1.13) |
0.92 (0.78, 1.14) |
| pre_HGB_180days |
12.30 (11.00, 13.50) |
12.30 (10.90, 13.60) |
| Missing |
1 |
0 |
| pre_ALB_180days |
4.00 (3.70, 4.30) |
4.00 (3.70, 4.20) |
| Missing |
3 |
0 |
| eGFR_CRE_baseline |
77 (67, 87) |
78 (63, 90) |
logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,661 |
1.70 |
1.51, 1.93 |
<0.001 |
| male |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.75 |
0.58, 0.98 |
0.037 |
| Race |
1,661 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
2.02 |
0.54, 7.90 |
0.295 |
| Other/Unknown |
|
0.88 |
0.26, 3.19 |
0.836 |
| White |
|
1.17 |
0.49, 3.45 |
0.748 |
| dm |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.28 |
1.58, 3.26 |
<0.001 |
| htn |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.96 |
1.47, 2.63 |
<0.001 |
| cad |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.69 |
1.23, 2.31 |
<0.001 |
| cirrhosis |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.12, 2.82 |
0.746 |
| ace_arb |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.39 |
1.82, 3.16 |
<0.001 |
| diu |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.48 |
1.87, 3.33 |
<0.001 |
| ppi |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.70 |
1.21, 2.44 |
0.003 |
| steroids |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.67, 1.19 |
0.410 |
| smoking |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.79 |
1.36, 2.36 |
<0.001 |
| statins |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.80 |
1.37, 2.39 |
<0.001 |
| nephrotoxic_chemo |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.33 |
1.01, 1.75 |
0.040 |
| Bevacizumab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.65 |
0.92, 2.82 |
0.078 |
| Cisplatin |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.18 |
0.77, 1.76 |
0.434 |
| Carboplatin |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.52 |
1.12, 2.06 |
0.007 |
| Pemetrexed |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.62 |
1.08, 2.37 |
0.016 |
| Gemcitabine |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.37 |
0.87, 2.11 |
0.160 |
| Cetuximab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.967 |
| Trastuzumab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.73 |
0.21, 1.86 |
0.553 |
| eGFR_CRE_baseline_decrease_10 |
1,661 |
1.32 |
1.23, 1.41 |
<0.001 |
| ICI_Class |
1,661 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
0.81 |
0.51, 1.24 |
0.350 |
| CTLA4 |
|
1.06 |
0.61, 1.74 |
0.827 |
| PDL1 |
|
1.30 |
0.88, 1.90 |
0.178 |
| cancer_group |
1,661 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.75 |
1.52, 4.84 |
<0.001 |
| gu |
|
2.28 |
1.51, 3.43 |
<0.001 |
| gyn |
|
2.20 |
1.09, 4.16 |
0.020 |
| other |
|
1.03 |
0.67, 1.56 |
0.897 |
| thoracic |
|
2.04 |
1.42, 2.93 |
<0.001 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,661 |
1.54 |
1.32, 1.79 |
<0.001 |
| male |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.64 |
0.47, 0.86 |
0.003 |
| dm |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.68 |
1.13, 2.49 |
0.010 |
| htn |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.06 |
0.76, 1.49 |
0.737 |
| cad |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.75, 1.52 |
0.696 |
| ppi |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.45 |
1.01, 2.13 |
0.049 |
| smoking |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.31 |
0.97, 1.79 |
0.083 |
| eGFR_CRE_baseline_decrease_10 |
1,661 |
1.14 |
1.05, 1.25 |
0.002 |
| nephrotoxic_chemo |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.98 |
0.69, 1.38 |
0.914 |
| ICI_Class |
1,661 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.23 |
0.75, 1.96 |
0.403 |
| CTLA4 |
|
1.74 |
0.96, 3.04 |
0.059 |
| PDL1 |
|
1.00 |
0.65, 1.52 |
0.984 |
| cancer_group |
1,661 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.82 |
1.48, 5.22 |
0.001 |
| gu |
|
1.98 |
1.20, 3.24 |
0.007 |
| gyn |
|
1.86 |
0.84, 3.94 |
0.115 |
| other |
|
1.34 |
0.83, 2.14 |
0.223 |
| thoracic |
|
1.78 |
1.11, 2.84 |
0.016 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,661 |
1.55 |
1.33, 1.82 |
<0.001 |
| male |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.65 |
0.48, 0.88 |
0.005 |
| dm |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.66 |
1.11, 2.46 |
0.012 |
| htn |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.74, 1.46 |
0.836 |
| cad |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.11 |
0.77, 1.57 |
0.575 |
| ppi |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.43 |
0.99, 2.10 |
0.059 |
| smoking |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.31 |
0.96, 1.78 |
0.089 |
| eGFR_CRE_baseline_decrease_10 |
1,661 |
1.15 |
1.05, 1.25 |
0.002 |
| Bevacizumab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.44 |
0.74, 2.70 |
0.268 |
| Cisplatin |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.63, 1.67 |
0.890 |
| Carboplatin |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.21 |
0.78, 1.86 |
0.383 |
| Pemetrexed |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.10 |
0.63, 1.93 |
0.739 |
| Gemcitabine |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.87 |
0.50, 1.47 |
0.600 |
| Cetuximab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.00 |
|
0.977 |
| Trastuzumab |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.96 |
0.27, 2.74 |
0.949 |
| ICI_Class |
1,661 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.24 |
0.75, 1.98 |
0.382 |
| CTLA4 |
|
1.75 |
0.96, 3.07 |
0.057 |
| PDL1 |
|
0.98 |
0.63, 1.49 |
0.915 |
| cancer_group |
1,661 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.69 |
1.41, 5.00 |
0.002 |
| gu |
|
1.99 |
1.20, 3.28 |
0.007 |
| gyn |
|
1.45 |
0.62, 3.27 |
0.377 |
| other |
|
1.39 |
0.86, 2.21 |
0.176 |
| thoracic |
|
1.53 |
0.92, 2.54 |
0.099 |
Multivariate logistic regression outcome: ckd_composite_5year
| Characteristic |
N |
OR |
95% CI |
p-value |
| year_10 |
1,661 |
1.53 |
1.31, 1.79 |
<0.001 |
| male |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.64 |
0.47, 0.86 |
0.003 |
| dm |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.67 |
1.11, 2.49 |
0.012 |
| htn |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.05 |
0.75, 1.49 |
0.764 |
| cad |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.07 |
0.75, 1.52 |
0.708 |
| ppi |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.45 |
1.01, 2.13 |
0.051 |
| smoking |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.31 |
0.97, 1.79 |
0.084 |
| eGFR_CRE_baseline_decrease_10 |
1,661 |
1.14 |
1.05, 1.25 |
0.002 |
| nephrotoxic_chemo |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.98 |
0.70, 1.39 |
0.919 |
| statins |
1,661 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.75, 1.43 |
0.851 |
| ICI_Class |
1,661 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.23 |
0.75, 1.96 |
0.404 |
| CTLA4 |
|
1.74 |
0.96, 3.04 |
0.060 |
| PDL1 |
|
1.00 |
0.65, 1.52 |
0.985 |
| cancer_group |
1,661 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
2.83 |
1.48, 5.23 |
0.001 |
| gu |
|
1.98 |
1.20, 3.23 |
0.007 |
| gyn |
|
1.86 |
0.84, 3.94 |
0.114 |
| other |
|
1.34 |
0.83, 2.13 |
0.225 |
| thoracic |
|
1.77 |
1.11, 2.83 |
0.016 |
Fine & Grey model for all
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
17,718 |
1.37 |
1.31, 1.43 |
<0.001 |
| male |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.87 |
0.78, 0.98 |
0.022 |
| Race |
17,718 |
|
|
|
| Asian |
|
— |
— |
|
| Black |
|
1.29 |
0.77, 2.17 |
0.340 |
| Other/Unknown |
|
1.14 |
0.69, 1.88 |
0.600 |
| White |
|
1.41 |
0.96, 2.08 |
0.082 |
| dm |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.53 |
1.32, 1.76 |
<0.001 |
| htn |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.46 |
1.28, 1.66 |
<0.001 |
| cad |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.19 |
1.04, 1.36 |
0.010 |
| cirrhosis |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.78 |
0.51, 1.20 |
0.260 |
| ace_arb |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
2.08 |
1.84, 2.34 |
<0.001 |
| diu |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.84 |
1.62, 2.09 |
<0.001 |
| ppi |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.31 |
1.14, 1.52 |
<0.001 |
| steroids |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.84 |
0.74, 0.96 |
0.010 |
| smoking |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.38 |
1.23, 1.56 |
<0.001 |
| statins |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.92 |
1.70, 2.17 |
<0.001 |
| nephrotoxic_chemo |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.93 |
0.83, 1.05 |
0.230 |
| Bevacizumab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.69 |
0.53, 0.90 |
0.005 |
| Cisplatin |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.02 |
0.86, 1.22 |
0.810 |
| Carboplatin |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.91, 1.17 |
0.590 |
| Pemetrexed |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.66 |
1.43, 1.92 |
<0.001 |
| Gemcitabine |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.09 |
0.92, 1.30 |
0.320 |
| Cetuximab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.42 |
0.24, 0.74 |
0.003 |
| Trastuzumab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.77 |
0.51, 1.16 |
0.210 |
| eGFR_CRE_baseline_decrease_10 |
17,718 |
1.20 |
1.18, 1.23 |
<0.001 |
| ICI_Class |
17,718 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.08 |
0.90, 1.30 |
0.400 |
| CTLA4 |
|
1.23 |
0.94, 1.59 |
0.130 |
| PDL1 |
|
1.11 |
0.94, 1.31 |
0.200 |
| cancer_group |
17,718 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.79 |
0.63, 0.98 |
0.036 |
| gu |
|
1.55 |
1.28, 1.88 |
<0.001 |
| gyn |
|
0.81 |
0.60, 1.11 |
0.200 |
| other |
|
0.54 |
0.44, 0.67 |
<0.001 |
| thoracic |
|
1.12 |
0.94, 1.33 |
0.200 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
17,718 |
1.21 |
1.14, 1.28 |
<0.001 |
| male |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.77 |
0.67, 0.87 |
<0.001 |
| dm |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.27 |
1.09, 1.49 |
0.002 |
| htn |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.03 |
0.89, 1.19 |
0.7 |
| cad |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.77, 1.02 |
0.10 |
| ppi |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.28 |
1.10, 1.49 |
0.001 |
| smoking |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.19 |
1.05, 1.35 |
0.009 |
| eGFR_CRE_baseline_decrease_10 |
17,718 |
1.12 |
1.08, 1.15 |
<0.001 |
| Bevacizumab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.68, 1.16 |
0.4 |
| Cisplatin |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.96 |
0.80, 1.17 |
0.7 |
| Carboplatin |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.89 |
0.76, 1.04 |
0.14 |
| Pemetrexed |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.82 |
1.49, 2.22 |
<0.001 |
| Gemcitabine |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.99 |
0.82, 1.20 |
>0.9 |
| Cetuximab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.70 |
0.39, 1.24 |
0.2 |
| Trastuzumab |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.06 |
0.69, 1.63 |
0.8 |
| ICI_Class |
17,718 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.11 |
0.92, 1.35 |
0.3 |
| CTLA4 |
|
1.29 |
0.98, 1.69 |
0.068 |
| PDL1 |
|
1.07 |
0.90, 1.27 |
0.4 |
| cancer_group |
17,718 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.83 |
0.66, 1.05 |
0.13 |
| gu |
|
1.30 |
1.05, 1.62 |
0.016 |
| gyn |
|
0.80 |
0.57, 1.12 |
0.2 |
| other |
|
0.68 |
0.54, 0.85 |
<0.001 |
| thoracic |
|
0.81 |
0.65, 1.01 |
0.061 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
17,718 |
1.20 |
1.13, 1.27 |
<0.001 |
| male |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.75 |
0.67, 0.85 |
<0.001 |
| dm |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.26 |
1.08, 1.47 |
0.003 |
| htn |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.04 |
0.90, 1.20 |
0.6 |
| cad |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.88 |
0.76, 1.01 |
0.074 |
| ppi |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.30 |
1.12, 1.52 |
<0.001 |
| smoking |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.20 |
1.06, 1.37 |
0.005 |
| eGFR_CRE_baseline_decrease_10 |
17,718 |
1.11 |
1.08, 1.15 |
<0.001 |
| nephrotoxic_chemo |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.96 |
0.84, 1.10 |
0.6 |
| ICI_Class |
17,718 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.08 |
0.89, 1.31 |
0.4 |
| CTLA4 |
|
1.27 |
0.97, 1.67 |
0.080 |
| PDL1 |
|
1.01 |
0.85, 1.20 |
>0.9 |
| cancer_group |
17,718 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.85 |
0.67, 1.06 |
0.2 |
| gu |
|
1.31 |
1.06, 1.62 |
0.013 |
| gyn |
|
0.76 |
0.55, 1.06 |
0.11 |
| other |
|
0.65 |
0.52, 0.81 |
<0.001 |
| thoracic |
|
1.04 |
0.85, 1.26 |
0.7 |
Fine & Grey model for all multivaiate model
| Characteristic |
N |
HR |
95% CI |
p-value |
| year_10 |
17,718 |
1.17 |
1.10, 1.24 |
<0.001 |
| male |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.74 |
0.65, 0.83 |
<0.001 |
| dm |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.18 |
1.01, 1.38 |
0.033 |
| htn |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.98 |
0.84, 1.13 |
0.7 |
| cad |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.84 |
0.73, 0.97 |
0.014 |
| ppi |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.26 |
1.08, 1.46 |
0.003 |
| smoking |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.18 |
1.04, 1.34 |
0.011 |
| eGFR_CRE_baseline_decrease_10 |
17,718 |
1.11 |
1.08, 1.14 |
<0.001 |
| nephrotoxic_chemo |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
0.95 |
0.83, 1.09 |
0.5 |
| statins |
17,718 |
|
|
|
| 0 |
|
— |
— |
|
| 1 |
|
1.44 |
1.25, 1.65 |
<0.001 |
| ICI_Class |
17,718 |
|
|
|
| PD1 |
|
— |
— |
|
| Combination |
|
1.08 |
0.89, 1.31 |
0.4 |
| CTLA4 |
|
1.27 |
0.97, 1.67 |
0.080 |
| PDL1 |
|
1.01 |
0.85, 1.19 |
>0.9 |
| cancer_group |
17,718 |
|
|
|
| cutaneous / melanoma |
|
— |
— |
|
| gi |
|
0.88 |
0.70, 1.11 |
0.3 |
| gu |
|
1.34 |
1.08, 1.66 |
0.008 |
| gyn |
|
0.80 |
0.57, 1.11 |
0.2 |
| other |
|
0.66 |
0.53, 0.83 |
<0.001 |
| thoracic |
|
1.04 |
0.85, 1.27 |
0.7 |